附子理中汤及其加减方对溃疡性结肠炎疗效的系统评价

doi:10.3969/j.issn.1674-490X.2018.05.005

医学研究与教育 ›› 2018, Vol. 35 ›› Issue (5): 23-31.DOI: 10.3969/j.issn.1674-490X.2018.05.005

附子理中汤及其加减方对溃疡性结肠炎疗效的系统评价

张丽惠,任晨华,张国伟

河北大学中医学院, 河北保定 071000

收稿日期:2018-03-06 出版日期:2018-10-25 发布日期:2018-10-25
通讯作者: 张国伟(1981—),男,河南新乡人,副教授,博士,主要从事中西医结合临床研究。E-mail: xxzgw@126.com
作者简介:张丽惠(1993—),女,河北唐山人,在读硕士,主要从事中西医结合临床研究。 E-mail: 773574050@qq.com
基金资助:
河北省自然科学基金(H2018201179);河北省高等学校自然科学研究青年基金(QN2016077);河北省医学科学研究重点课题(20160388)

Received:2018-03-06 Online:2018-10-25 Published:2018-10-25

摘要/Abstract

摘要： 目的对附子理中汤及其加减方治疗溃疡性结肠炎的疗效进行系统评价,并总结其治疗溃疡性结肠炎的临床疗效及安全性。方法按照Cochrane系统评价的方法,在CNKI、VIP、万方数据以及PubMed、EMBase、Medline、Cochrane Library等数据库中检索文献,查找应用附子理中汤及其加减方治疗溃疡性结肠炎的随机对照试验和半随机对照试验。经过筛选纳入符合条件的临床随机对照试验(randomized controlled trail, RCT),对所纳入的研究进行数据提取和质量评价后,应用RevMan 5.3软件进行Meta分析,应用GRADE系统对证据质量和等级推荐进行评分。结果一共纳入8项符合条件的RCT研究,共有688名患者参加符合条件的临床研究,但这8项研究方法学质量均较差。Meta分析结果显示:总有效率OR合并=4.32［OR=4.32,95%CI(2.55,7.31),P<0.000 01］。GRADE系统评价结果显示,证据水平均为B,推荐等级为弱推荐。结论采用附子理中汤及其加减方治疗溃疡性结肠炎有效率高于单纯西药治疗,且有较高的安全性,无明显的不良反应。由于纳入的临床对照研究质量有不足,所以附子理中汤及其加减方治疗溃疡性结肠炎的疗效尚不能做出最后的结论,仍然需要更多高质量的RCT才能得出肯定的结论。

关键词: 附子理中汤, 溃疡性结肠炎, Meta分析, 系统评价, GRADE系统

Abstract: Objective To evaluate Fuzilizhong decoction and its modified decoction systematically and summarize the clinical efficacy and safety of the treatment of ulcerative colitis. Methods According to the Cochrane system evaluation method, we searched the database of CNKI,VIP and Wanfang as well as in PubMed,EMBase,Medline,Cochrane Library database to search some randomized controlled trials and a semi randomized controlled trials of Fuzi Lizhong Decoction and its addition and subtraction in the treatment of ulcerative colitis. For eligible RCT, after data extraction and quality evaluation, RevMan 5.3 software was applied in Meta analysis, and GRADE system was used to score the quality and grade recommendation. Results A total of 8 eligible RCT studies were included, with a total of 688 patients participating in qualified clinical studies, but their methodological quality was poor. Meta analysis showed that the total effective rate was OR combined with OR=4.32［OR=4.32, 95%CI(2.55, 7.31), P<0.000 01］. Fuzilizhong decoction had no obvious adverse reactions in the treatment of ulcerative colitis, and had good safety. The results of GRADE system evaluation showed that the level of evidence was B, and the recommendation level was weak recommendation. Conclusion The effective rate of Fuzi Lizhong Decoction and its addition and subtraction therapy is higher than that of western medicine alone, and it had high safety and no obvious side effects. Due to the low quality of the clinical controlled studies, the curative effect of Fuzilizhong decoction and its addition and subtraction prescription on ulcerative colitis is still unable to make the final conclusion. More high-quality RCT is needed to get a positive conclusion.

Key words: Fuzilizhong decoction, ulcerative colitis, meta analysis, systematic evaluation, GRADE system

中图分类号:

张丽惠,任晨华,张国伟. 附子理中汤及其加减方对溃疡性结肠炎疗效的系统评价[J]. 医学研究与教育, 2018, 35(5): 23-31.

参考文献

[1] 江学良,权启镇,王志奎.溃疡性结肠炎的诊断、分型及疗效标准[J].世界华人消化杂志,2000(3):332-334.DOI:10.3969/j.issn.1009-3079.2000.03.027.
[2] 宋良,张进峰,郜艳丽.中西医结合治疗慢性溃疡性结肠炎131例[J].河南中医学院学报,2003,18(1):47-48.DOI:10.3969/j.issn.1674-8999.2003.01.022.
[3] SCHROEDER K W,TREMAINE W J,ILSTRUP D M. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study[J]. New England Journal of Medicine,1987,317(26): 1625-1629.DOI:10.1056/NEJM198712243172603.
[4] MARZILLI M, KLEIN W W. Efficacy and tolerability of trimetazidine in stable angina: a meta-analysis of randomized, double-blind, controlled trials[J]. Coronary Artery Disease, 2003, 14(2): 171-179.DOI:10.1097/01.mca.0000062799.53287.82.
[5] 李慧儒.附子理中芍桂汤加减治疗慢性溃疡性结肠炎98例[J].现代中医药,2007(2):24-25.DOI:10.3969/j.issn.1672-0571.2007.02.015.
[6] 刘继业,李丰林.附子理中汤合四神丸加味治疗脾肾阳虚型溃疡性结肠炎临床观察[J].中国肛肠病杂志,2016,36(9):38-41.DOI:10.3969/j.issn.1000-1174.2016.09.017.
[7] 陈军,鲁磊,刘志国.加味附子理中汤治疗脾肾阳虚型溃疡性结肠炎疗效观察[J].中国中西医结合消化杂志,2014,22(10):624-625.DOI:10.3969/j.issn.1671-038X.2014.10.20.
[8] 余海平,张建兴,李春耕.附子理中汤加味治疗慢性溃疡性结肠炎的临床评价[J].中国药业,2017,26(13):67-69.DOI:10.3969/j.issn.1006-4931.2017.13.024.
[9] 刘彩莉,李卫河.附子理中痛泻白头翁合方治疗溃疡性结肠炎[J].新乡医学院学报,1997(1):72-74.
[10] 叶道冰,宋红旗,牛明了.康复新液联合附子理中散治疗溃疡性结肠炎临床观察[J].新中医,2013,45(8):50-51.
[11] 余沅林.附子理中汤加味联合柳氮磺胺吡啶治疗溃疡性结肠炎的效果观察[J].当代医学,2016,22(35):192-193.DOI:10.3969/j.issn.1009-4393.2016.35.125.
[12] 肖福香,万莉华,陈舞燕.加味附子理中汤应用于脾肾阳虚型溃疡性结肠炎治疗的有效性分析[J].数理医药学杂志,2016,29(6):874-875.DOI:10.3969/j.issn.1004-4337.2016.06.040.
[13] 曾宪涛,冷卫东,李胜,等.如何正确理解及使用GRADE系统[J].中国循证医学杂志,2011,11(9):985-990.DOI:10.3969/j.issn.1672-2531.2011.09.002.
[14] 陈耀龙,李幼平,杜亮,等.医学研究中证据分级和推荐强度的演进[J].中国循证医学杂志,2008,8(2):127-133.DOI:10.3969/j.issn.1672-2531.2008.02.012.
[15] 裴强伟,孙志翠,宋小莉,等.半夏泻心汤及其加减方治疗溃疡性结肠炎疗效和安全性的系统评价[J].中国实验方剂学杂志,2012,18(14):290-294.DOI:10.3969/j.issn.1005-9903.2012.14.084.
[16] GUYATT G H, OXMAN A D, VIST G, 等.GRADE指南:IV.证据质量分级—研究的局限性(偏倚风险)[J]. 李幼平,杨晓妍,李鸿浩,等译.中国循证医学杂志, 2011, 11(4):456-463.DOI: 10.3969/j.issn.1672-2531,2011.04.018.
[17] 杨晋翔,安静,彭继升,等.半夏泻心汤加减方治疗慢性萎缩性胃炎临床疗效的系统评价[J].北京中医药大学学报,2015,38(1):46-52.DOI:10.3969/j.issn.1006-2157.2015.01.011.
[18] 李青,夏芸,牟钰洁,等.国内中文期刊发表的中医药系统综述和Meta分析文献质量再评价[J].北京中医药大学学报(中医临床版),2012,19(3):28-33.DOI:10.3969/j.issn.1672-2205.2012.03.008.

附子理中汤及其加减方对溃疡性结肠炎疗效的系统评价

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 8

编辑推荐

Metrics

本文评价

[1]	罗发梦,刘蓉,张海燕. 炎症性肠病患者的药物管理研究进展[J]. 医学研究与教育, 2022, 39(2): 66-71.
[2]	杨阳,王珏,刘宁. 急性脑卒中患者吞咽障碍检出率的Meta分析[J]. 医学研究与教育, 2022, 39(2): 54-65.
[3]	王凡,袁正玺,白苗苗,徐月清,田晓红. 以夫妻为中心的心理干预对乳腺癌患者心理健康状况影响的Meta分析[J]. 医学研究与教育, 2021, 38(1): 64-69.
[4]	李娜,宋若飘,贾友超,臧爱民. AXL表达与乳腺癌预后及临床病理特征关系的Meta分析[J]. 医学研究与教育, 2020, 37(3): 18-27.
[5]	刘晓萌,陈松鹤,马立新. 益气养阴法治疗慢性萎缩性胃炎的系统评价[J]. 医学研究与教育, 2019, 36(2): 39-47.
[6]	耿丽梅,马晓莉,刘红燕. 天灸疗法对溃疡性结肠炎缓解期的疗效观察[J]. 医学研究与教育, 2011, 28(2): 53-56.
[7]	王艳芬,张建民. 溃疡性结肠炎的危险因素[J]. 医学研究与教育, 2010, 27(3): 57-60.
[8]	田自力,康小红,路玉香,徐世聪,孟杰,赵淑琴. 穴位埋线联合柳氮磺胺吡啶治疗溃疡性结肠炎的疗效观察[J]. 医学研究与教育, 2009, 26(4): 36-37.